Ntla stock rating
About NTLA. Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and NTLA:NASDAQ. Add to Watchlist +. Trade. {{ portfolio.portfolio_name }}; You have no watchlists at this time, click " Dividend History for Intellia Therapeutics Inc (NASDAQ:NTLA). Click to see Stock Price Quote detail and other financial information on NTLA, or here to see 16 Mar 2020 Analysts Estimation on Stock: The current analyst consensus rating stood at 2 on shares (where according to data provided by FINVIZ, 1.0 Strong View today's stock price, news and analysis for Intellia Therapeutics Inc. (NTLA). Barron's also provides information on historical stock ratings, target prices, In depth view into NTLA (Intellia Therapeutics) stock including the latest price, news, dividend history, earnings information and financials.
Intellia Therapeutics (NASDAQ:NTLA) ‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a research note issued on Tuesday, TipRanks reports. They presently have a $57.50 price target on the stock. Chardan Capital’s target price would suggest a potential upside of 370.16% from the company’s current price.
NTLA - Stock Quote, Stock Technical Analysis, Stock Rating From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term. NTLA has closed below upper band by 1.9%. Bollinger Bands are 73.5% wider than normal. The large width of the bands … TheStreet Ratings - Stock, ETF and Mutual Fund Ratings and ... Stock Ratings. Of what use are stock ratings if little consideration is given to investment risk? Unlike many other rating agencies, we analyze both fundamental and technical risk factors, so NTLA:NASDAQ GM Stock Quote - Intellia Therapeutics Inc ...
Apr 03, 2020 · Stock quote and company snapshot for INTELLIA THERAPEUTICS INC (NTLA), including profile, stock chart, recent news and events, analyst opinions, and research reports.
From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term. NTLA has closed below upper band by 1.9%. Bollinger Bands are 73.5% wider than normal. The large width of the bands … TheStreet Ratings - Stock, ETF and Mutual Fund Ratings and ... Stock Ratings. Of what use are stock ratings if little consideration is given to investment risk? Unlike many other rating agencies, we analyze both fundamental and technical risk factors, so NTLA:NASDAQ GM Stock Quote - Intellia Therapeutics Inc ... Stock analysis for Intellia Therapeutics Inc (NTLA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Oppenheimer Sticks to Their Hold Rating for Intellia ...
Filter NTLA News Items All News Types Featured Stories Commentary Corp. News Cramer Debt Offering Downgrade Earnings IPOs Mgmt Change New Coverage (Bullish) New Coverage (Neutral) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bullish) Resumes Coverage (Bullish) Stock Offering Upgrade
The stock was given Neutral rating by ROTH Capital in its report released on June 10, 2019, the day when the price target on the stock was placed at 16. Wedbush was of a view that NTLA is Outperform in its latest report on May 03, 2019. Evercore ISI thinks that NTLA is worth Outperform rating. Intellia Therapeutics - investor relations The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts.
Seeking Alpha's authors provide a stock rating for Intellia Therapeutics, Inc. (NTLA). Ratings range from 'Very Bullish' to 'Very Bearish'.
Intellia Therapeutics’ (NTLA) “Buy” Rating Reaffirmed at ... 4 days ago · Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “buy” rating reaffirmed by investment analysts at BTIG Research in a research report issued on Thursday, TipRanks reports. They presently have a $22.00 price objective on the stock. BTIG Research’s target price would suggest a potential upside of 84.87% from the stock’s previous close. NTLA Intellia Therapeutics — Stock Price and Discussion ... Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures.
Intellia Thera CS (NTLA) Intellia Thera CS (NTLA) (NTLA) stock based on the movements in the options market lately. NTLA: 11.92 each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in